Stefan Janssen1,2, Lukas Kaesmann1, Volker Rudat3, Dirk Rades4. 1. Department of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. 2. Medical Practice for Radiotherapy and Radiation Oncology, Hannover, Germany. 3. Department of Radiation Oncology, Saad Specialist Hospital, Al Khobar, Saudi Arabia. 4. Department of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. rades.dirk@gmx.net.
Abstract
INTRODUCTION: The main goal of the present study was the development of a survival scoring system for patients treated with stereotactic body radiation therapy (SBRT) for very few lung metastases. Such an instrument would be of value when selecting the optimal dose for individual patients with a limited number of pulmonary lesions. METHODS: Forty-six patients receiving SBRT for 1-3 lung metastases were retrospectively analyzed. The biologically effective dose plus nine characteristics [gender, age, performance score, interval from tumor diagnosis to SBRT, primary tumor type, additional (extra-pulmonary) metastases, major location of lung metastases, number of pulmonary lesions, and volume treated with SBRT] were evaluated. Characteristics significantly associated with the survival on Cox regression analysis were incorporated in the scoring system. Scoring points were received from 1-year survival rates divided by 10. Sums of these scoring points represented the scores for the individual patients. RESULTS: Survival rates at 1 and 2 years were 66 and 56 %, respectively. On Cox regression analysis, performance score (p = 0.025), the type of primary tumor (p = 0.013) and the additional metastases (p = 0.032) had a significant impact on survival. Scores for patients ranged from 15 to 25 points. Three groups were designed: 15 points, 16-20 points, and 21-25 points. One-year survival rates were 0, 52, and 83 %, respectively (p = 0.005); 2-year survival rates were 0, 52, and 66 %, respectively. CONCLUSION: A survival scoring system for patients receiving SBRT for very few lung metastases was developed. This score allowed us to estimate the survival prognosis of these patients and can aid physicians when aiming to choose the optimal SBRT dose for individual patients.
INTRODUCTION: The main goal of the present study was the development of a survival scoring system for patients treated with stereotactic body radiation therapy (SBRT) for very few lung metastases. Such an instrument would be of value when selecting the optimal dose for individual patients with a limited number of pulmonary lesions. METHODS: Forty-six patients receiving SBRT for 1-3 lung metastases were retrospectively analyzed. The biologically effective dose plus nine characteristics [gender, age, performance score, interval from tumor diagnosis to SBRT, primary tumor type, additional (extra-pulmonary) metastases, major location of lung metastases, number of pulmonary lesions, and volume treated with SBRT] were evaluated. Characteristics significantly associated with the survival on Cox regression analysis were incorporated in the scoring system. Scoring points were received from 1-year survival rates divided by 10. Sums of these scoring points represented the scores for the individual patients. RESULTS: Survival rates at 1 and 2 years were 66 and 56 %, respectively. On Cox regression analysis, performance score (p = 0.025), the type of primary tumor (p = 0.013) and the additional metastases (p = 0.032) had a significant impact on survival. Scores for patients ranged from 15 to 25 points. Three groups were designed: 15 points, 16-20 points, and 21-25 points. One-year survival rates were 0, 52, and 83 %, respectively (p = 0.005); 2-year survival rates were 0, 52, and 66 %, respectively. CONCLUSION: A survival scoring system for patients receiving SBRT for very few lung metastases was developed. This score allowed us to estimate the survival prognosis of these patients and can aid physicians when aiming to choose the optimal SBRT dose for individual patients.
Authors: Dirk Rades; Sarah Douglas; Theo Veninga; Lukas J A Stalpers; Peter J Hoskin; Amira Bajrovic; Irenaeus A Adamietz; Hiba Basic; Juergen Dunst; Steven E Schild Journal: Cancer Date: 2010-08-01 Impact factor: 6.860
Authors: Haoming Qiu; Alan W Katz; Amit K Chowdhry; Kenneth Y Usuki; Deepinder P Singh; Su Metcalfe; Praveena Cheruvu; Yuhchyau Chen; Paul Okunieff; Michael T Milano Journal: Am J Clin Oncol Date: 2018-01 Impact factor: 2.339
Authors: Allison B Ashworth; Suresh Senan; David A Palma; Marc Riquet; Yong Chan Ahn; Umberto Ricardi; Maria T Congedo; Daniel R Gomez; Gavin M Wright; Giulio Melloni; Michael T Milano; Claudio V Sole; Tommaso M De Pas; Dennis L Carter; Andrew J Warner; George B Rodrigues Journal: Clin Lung Cancer Date: 2014-05-15 Impact factor: 4.785
Authors: Marie-Adele S Kress; Brian T Collins; Sean P Collins; Anatoly Dritschilo; Gregory Gagnon; Keith Unger Journal: Radiat Oncol Date: 2012-09-05 Impact factor: 3.481
Authors: Dirk Rades; Oliver Blanck; Mai Trong Khoa; Pham VAN Thai; Nguyen Quang Hung; Liesa Dziggel; Steven E Schild Journal: In Vivo Date: 2018 Mar-Apr Impact factor: 2.155
Authors: Kerstin A Kessel; Rebekka C E Grosser; Kim Melanie Kraus; Hans Hoffmann; Markus Oechsner; Stephanie E Combs Journal: BMC Cancer Date: 2020-05-19 Impact factor: 4.430